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Abstract
Human mesenchymal stem cells (hMSCs) display immunosuppressive properties in vitro and the potential has also been
transferred successfully to clinical trials for treatment of autoimmune diseases. OX-2 (CD200), a member of the
immunoglobulin superfamily, is widely expressed in several tissues and has recently been found from hMSCs. The CD200
receptor (CD200R) occurs only in myeloid-lineage cells. The CD200-CD200R is involved in down-regulation of several
immune cells, especially macrophages. The present study on 20 hMSC lines shows that the CD200 expression pattern varied
from high (CD200Hi) to medium (CD200Me) and low (CD200Lo) in bone marrow-derived mesenchymal stem cell (BMMSC)
lines, whereas umbilical cord blood derived mesenchymal stem cells (UCBMSCs) were constantly negative for CD200. The
role of the CD200-CD200R axis in BMMSCs mediated immunosuppression was studied using THP-1 human macrophages.
Interestingly, hMSCs showed greater inhibition of TNF-a secretion in co-cultures with IFN-c primed THP-1 macrophages
when compared to LPS activated cells. The ability of CD200Hi BMMSCs to suppress TNF-a secretion from IFN-c stimulated
THP-1 macrophages was significantly greater when compared to CD200Lo whereas UCBMSCs did not significantly reduce
TNF-a secretion. The interference of CD200 binding to the CD200R by anti-CD200 antibody weakened the capability of
BMMSCs to inhibit TNF-a secretion from IFN-c activated THP-1 macrophages. This study clearly demonstrated that the
efficiency of BMMSCs to suppress TNF-a secretion of THP-1 macrophages was dependent on the type of stimulus. Moreover,
the CD200-CD200r axis could have a previously unidentified role in the BMMSC mediated immunosuppression.
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Introduction
The immune system can be classified into adaptive and innate
immune responses and their complex interplay is crucial to
achieve properly working defense system [1,2]. Macrophages are
central players in innate immunity and they are classically divided
into the two phenotypes M1 (proinflammatory) and M2 (healing)
macrophages [1–3]. However, recent studies have shown that the
heterogeneity of macrophages is much wider and complex than
has previously been thought [4]. Bacterial lipopolysaccharide
(LPS) is commonly used to induce the M1 phenotype and further
the secretion of T helper 1 (Th1) cytokines, such as tumor necrosis
factor-alpha (TNF-a), interleukin-1b or interleukin-6 [3]. Inter-
feron-gamma (IFN-c) is also an important activator or primer of
macrophages and other immune cells [5]. IFN-c is mainly
produced by Th1-cells and natural killer cells. The presence of
IFN-c has been shown to be elevated in many inflammatory
conditions and also to be relevant during macrophage activation in
several autoimmune diseases [3,6–9]. A recent proteome biopro-
filing study has also revealed differences between LPS and IFN-c
activation of macrophages, in which the un-stimulated macro-
phages could be distinguished from IFN-c primed and LPS
activated ones [10].
Human mesenchymal stem cells (hMSCs) have shown immu-
nosuppressive properties which are mediated through modifying
both innate and adaptive immune systems [11–15]. hMSC-based
cellular therapies have shown their usefulness in treatment of
autoimmune diseases, such as Crohn’s disease, graft versus host
disease (GVHD) and diabetes [16–19]. The role of different
soluble factors secreted by hMSCs, such as kynurenines produced
by the tryptophan-degrading enzyme indoleamine-2,3-dioxygen-
ase-1 (IDO1), prostaglandin E2 (PGE2), transforming growth
factor beta (TGF-b) and galectin-1 have been demonstrated
[11,20–22].
Recently the cell-cell interactions between hMSCs and different
immune cells have also been studied and the role of the intercellular
adhesion molecule-1 (ICAM-1), the vascular cell adhesion mole-
cule-1 (VCAM-1) and Thy-1 (CD90) has been shown in hMSC
mediated immunosuppression [23,24]. OX-2 (CD200), a mem-
brane glycoprotein which belongs to the immunoglobulin super-
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suggested to be a marker of native hMSC population [25–27]. On
the other hand, expression of the CD200 receptor (CD200R) is
restricted only to the myeloid lineage cells [28] and CD200 binding
to the CD200R is shown to suppress the activity of many immune
cells butespecially macrophages [29–32]. Murineknock-out models
have demonstrated the importance of the CD200-CD200R axis in
controlling macrophage activity also in vivo and the immunosup-
pressive capacity of CD200R agonist has been demonstrated in vitro
and also in vivo in collagen induced arthritis models [29,33–35]. In
addition, murine knock-out models in skin graft experiments have
shown the important role of the CD200 interaction with CD200R
in skin engraftment [36].
Only a few studies have previously examined the interactions
between human macrophages and hMSCs [37,38], whereas the
CD200-CD200r axis has been shown to be relevant especially in
regulation of macrophages. Accordingly, the present study strives
to elucidate the role of the CD200-CD200R axis in bone marrow-
derived mesenchymal stem cells (BMMSCs) mediated immune
modulation of THP-1 macrophage-like cells.
Methods
hMSC Isolation and Culture
Northern Ostrobothnia Hospital District Ethical committee has
approved the collection of human mesenchymal stem cells from
patients from Oulu University Hospital after written consent.
Isolation and culture of BMMSCs: BMMSCs were isolated from
an unaffected bone site of patients who were operated for
osteoarthritis and from some younger patients operated for
idiopathic scoliosis as described earlier [39]. To control the
quality of BMMSC lines, patients with neuromuscular scoliosis,
autoimmune diseases such as rheumatoid arthritis, or genetic
diseases were excluded. Samples from bone marrow were
suspended in a proliferation medium containing alpha minimum
essential medium (aMEM) buffered with 20 mM HEPES and
containing 10% heat-inactivated fetal bovine serum (FBS), 100 U/
ml penicillin, 0.1 mg/ml streptomycin and 2 mM L-glutamine,
and the suspension was transferred into cell culture flask. hMSCs
were allowed to attach for 48 hours at 37uC under 5% CO2 and
20% O2. Nonattached cells were removed by changing fresh
medium and attached cells were cultured in bottom of flask until
they reached 70–80% confluence. The medium was changed twice
a week and cells in passages 3–6 were used in experiments.
Cord blood collections were performed at the Helsinki
University Central Hospital, Department of Obstetrics and
Gynaecology, and Helsinki Maternity Hospital after written
consent and study protocol was approved by ethical review board
of Helsinki University Central Hospital and the Finnish Red Cross
Blood Service. Isolation and culture of umbilical cord blood-
derived mesenchymal stem cells (UCBMSCs): Cord blood
collections were performed at the Helsinki University Central
Hospital (HUCH), Department of Obstetrics and Gynaecology,
and Helsinki Maternity Hospital. UCBMSCs were isolated and
expanded as described earlier [40]. Mononuclear cells were
isolated using Ficoll-Hypaque (Amersham Biosciences, Piscaway,
NJ, USA) gradient centrifugation. Tissue culture plates (Nunc)
were coated with fibronectin (Sigma) and mononuclear cells were
plated at a density of 1610
6/cm2. The initial UCBMSC line
establishment was performed under hypoxic conditions (5% CO2,
3% O2 at 37uC) in medium containing aMEM with Glutamax
(Gibco, Grand Island, NY, USA) and 10% fetal calf serum (Gibco)
supplemented with 10 ng/ml epidermal growth factor (EGF,
Sigma), 10 ng/ml recombinant human platelet-derived growth
factor (rhPDGF-BB; R&D Systems, Minneapolis, MN, USA),
50 nM Dexamethasone (Sigma), 100 U/ml penicillin together
with 100 m g/ml streptomycin (Invitrogen). Cells were allowed to
adhere overnight and non-adherent cells were washed out with
medium changes. Hence, UCBMSCs were cultured under
normoxic conditions (5% CO2 and 20% O2 at 37uC) and
proliferation media was renewed twice a week. Established lines
were passaged when almost confluent and replated at 1000–3000
cells/cm
2. Cells in passages 3–7 were used.
Differentiation of THP-1 Monocytes into Macrophage-like
Cells and Co-culture with hMSCs
The THP-1 human monocyte cell line from an acute monocytic
leukemia patient was obtained from ATCC (TIB-202) and cells
were expanded in RPMI 1640 medium (Lonza) supplemented
with 10% heat-inactivated FBS, 100 U/ml penicillin, 0.1 mg/ml
streptomycin and 2 mM L-glutamine (expansion medium). THP-1
monocytes were first cultured 2–3 weeks in T15 flask before their
differentiation was started. Fresh expansion medium was added
twice a week and at the end of the week cells were transferred to
the new T15 flask. To start differentiation, THP-1 cells were
suspended in the expansion medium supplemented with 100 ng/
ml phorbol 12-myristate 13-acetate (PMA, Sigma Aldrich) and
then 100 000 cells per well were added on 24-well plates and were
incubated for 48 h at 37uC under 5% CO2 and 20% O2. After
48 hours, most of the cells were attached to the bottom of plates
and PMA containing medium was removed. THP-1 macrophage
like cells were washed twice with phosphate-buffered saline (PBS)
followed by addition of co-culture assay medium containing
aMEM buffered with 20 mM HEPES and supplemented with
100 U/ml penicillin, 0.1 mg/ml streptomycin and 2 mM L-
glutamine. hMSCs were expanded as described above and
detached from the culture flask and suspended in the co-culture
assay medium. To start the co-culture, 100 000 hMSCs per well
were added (the final ratio of hMSCs and THP-1 macrophage
cells were 1:1) in 24-well plate where PMA-treated THP-1
macrophage-like cells already were plated and after that 100 ng/
ml LPS (purified from Escherichia coli 055:B5; Sigma Aldrich) or
100 ng/ml IFN-c (Sigma Aldrich) were added. During co-culture,
the total volume of medium in 24-well plate wells was 0.5 ml. Co-
culture was performed for 24 hours at 37uC under 5% CO2 and
20% O2 followed by the collection of supernatants for cytokine
assays. Controls included hMSCs alone, hMSCs with unstimu-
lated THP-1 macrophages, hMSCs in presence of 100 ng/ml LPS
or 100 ng/ml IFN-c to see whether hMSCs also secrete TNF-a.I n
addition, unstimulated THP-1 macrophage-like cells, 100 ng/ml
LPS activated THP-1 macrophage-like cells and 100 ng/ml IFN-c
activated THP-1 macrophage-like cells were included as controls
in which the co-cultures were compared. All co-cultures and
controls were performed in three replicates. The change in TNF-a
or IL-10 secretion was determined by comparing cytokine levels in
co-culture with hMSCs in the presence of LPS or IFN-c to the
cytokine levels in THP-1 macrophage-like cells alone in the
presence of LPS or IFN-c. Co-culture experiments were repeated
2–3 times and results are represented as a mean6SD of three
independent replicates of one experiment unless otherwise
indicated.
Mouse anti-human PE-conjugated CD200 antibody (BD
Biosciences) was used in some experiments to block CD200 in
hMSCs. For blocking, the hMSCs were incubated with anti-
human CD200 antibody for 20 minutes in PBS with 0.5% bovine
serum albumin (BSA) and then washed twice with PBS and
suspended in co-culture assay medium whereas the control cells of
the same hMSC pool remained untreated.
CD200 Positive hMSC Suppress Macrophage-Like Cells
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hMSCs were plated on sterile coverslips at a density of 5000
cells/well in 24-well plates in the proliferation medium and were
grown for 2–3 days. The medium was removed and cells were
fixed with 3% paraformaldehyde in PBS for 15 min followed by
washing twice with PBS. The cells were first incubated in PBS with
1.0% BSA for 1 hour at room temperature to block unspecific
binding. Phycoerythrin (PE) conjugated mouse anti-human
CD200 and fluorescein isothiocyanate (FITC) conjugated mouse
anti-human CD90 (Stem Cell Technologies Inc) were diluted in
PBS with 1.0% BSA (1:10) and cells were incubated over night at
4uC in dark and shaker. After incubation, the cells were washed
three times with PBS for 5 minutes and then incubated with
Hoechst in PBS with 1.0% BSA (1:1000) for 5 minutes in dark.
Hoechst was washed away with PBS and coverslips were mounted
to glass slides.
THP-1 cells were seeded on sterile coverslips at 100 000 cells/
well in 24-well plates and differentiated as stated above. The
differentiation media was removed and cells were washed and
incubated for 24 hours in assay medium alone, assay medium with
100 ng/ml LPS and assay medium with 100 ng/ml IFN-c. After
24 hours, medium was removed and cells were fixed with 3%
paraformaldehyde for 15 minutes and washed twice with PBS.
The cells were first blocked in PBS with 1.0% BSA for 1 hour at
room temperature. PE conjugated monoclonal anti-human
CD200R antibody (eBioscience) was diluted in PBS with 1.0%
BSA (1:10) and cells were incubated overnight at 4uC with shaking
in dark. Hoechst staining and mounting were performed as for
hMSCs. THP-1 macrophage-like cells and hMSCs were photo-
graphed using an Axio Lab.A1 microscope (Carl Zeiss Micro-
Imaging Gmbh, Germany).
Flow Cytomeric Analysis of Cell Surface Antigens
hMSCs were detached from the culture flask and suspended in
PBS with 0.5% BSA. The characterization of cell surface antigens
for hMSCs was performed by using the following conjugated
antibodies: CD44 (fluorescein isothiocyanate (FITC); BD Biosci-
ences), CD49e (phycoerythrin (PE); BD Biosciences), CD90
(FITC; Stem Cell Technologies, Grenoble, France), CD73 (PE;
BD Biosciences), HLA-ABC (allophycocyanin (APC; BD Biosci-
ences), CD54 (APC; BD Biosciences) and CD105 (FITC; Abcam,
Cambridge, United Kingdom). Negative surface antigens for
hMSCs were incubated simultaneously as a group in the same
sample: HLA-DR (PE; BD Biosciences), CD34 (PE; BD
Biosciences), CD45 (PE; BD Biosciences), CD14 (PE; BD
Biosciences), and CD19 (PE; BD Biosciences). Samples were
analyzed by using FACSCalibur (Becton Dickinson), equipped
with dual lasers emitting at 488 nm and 633 nm. The fluorescence
emissions were measured at 585 nm642 nm and data were
analyzed with FlowJo (TreeStar Inc. Ashland, OR). The gates for
positivity were individually defined by a negative control due to
the differences in autofluorescence between different hMSC lines.
Analysis of Cytokine Secretion by Enzyme-linked
Immunosorbent Assay (ELISA)
Supernatants were collected after 24 hours from hMSCs and
THP-1 cells co-cultures and stored at 270uC until analysis. TNF-
a and IL-10 levels were determined from supernatants as
described below. TNF-a and IL-10 capture antibodies (TNF-a,
BD Pharmingen; IL-10, BD Pharmingen) were diluted to 1 m g/ml
and incubated in maxi-sorp 96-well plates (Nunc) over night at
4uC. Following incubation, unbound capture antibodies were
removed and wells were blocked with PBS with 1.0% BSA (Sigma)
for 1 hour. Plates were washed with PBS supplemented with
Tween-20 (Sigma) and IL-10 and TNF-a standards (TNF-a,B D
Pharmingen; IL-10, BD Pharmingen) together with collected
supernatants followed by thawing and incubation in 96-well maxi-
sorp plates for two hours at room temperature. Samples were also
analyzed as 1:10 dilutions. Standards and supernatants were
diluted in the co-culture assay medium. After two hours of
incubation, standards and samples were removed and plates were
washed five times with PBS containing Tween-20. Biotin-labeled
IL-10 and TNF-a antibodies (IL-10, BD Pharmingen; TNF-a,B D
Pharmingen) were diluted to 0.25 m g/ml in PBS with 1.0% BSA
and Tween-20 and incubated for one hour at room temperature.
Wells were washed five times with PBS+Tween-20. Avidin-
horseradish peroxidase (HRP) conjugate (BD Pharmingen) was
diluted in PBS with 1.0% BSA and Tween-20 (1:1000) and was
incubated for 30 minutes. Avidin-HRP was removed and wells
were washed five times with PBS with Tween-20. Substrates of
3,39, 5,59 tetramethylbenzidine (TMB, PD Pharmingen) reagent
set were mixed in 1:1 and added to the wells and color
development was followed at 1 hour for IL-10 and 15 minutes
for TNF-a. The reaction was stopped with 1 M phosphoric acid
and absorbance was measured at 450 nm with ELISA plate-reader
(MultiScan). Cytokine concentrations were determined by Multi-
Calc software. Results from co-cultures are indicated as %-change
in cytokine secretion when compared to activated THP-1
macrophage-like cells alone.
Statistics
Statistical analysis and all diagrams were performed by using the
OriginPro version 8. All data are presented as mean 6 standard
deviation (SD) of the results from three independent replicates or
three different hMSC lines unless otherwise indicated. The
significance level was determined by two-sample t-test and one
way analysis of variance (ANOVA) when CD200 high, medium
and low BMMSCs were compared together. The p-value p,0.05
was considered as statistically significant.
Results
CD200 Expression Pattern Differences in hMSC Lines
BMMSCs differed in CD200 expression and high (CD200Hi),
medium (CD200Me) or low (CD200Lo) positivity for CD200
could be identified (Table 1). On the other hand, the three
studied UCBMSC lines were CD200 negative. Based on flow
cytometry analysis of the 20 different hMSC lines, the role of the
CD200-CD200R axis in hMSCs mediated immunosuppression
was further elucidated with following hMSC lines: CD200Hi 1
(Figure 1 A; 52.53% positivity for CD200), CD200Hi 2 (Figure 1
B; 69.59% positivity for CD200), CD200Me 1 (Figure 1 C;
26.86% positivity for CD200), CD200Me 2 (Figure 1 D; 17.21%
positivity for CD200), CD200Lo 1 (Figure 1 E; 8.31% positivity
for CD200), CD200Lo 2 (Figure 1 F; 7.50% positivity for
CD200), UCBMSC 1 (Figure 1 G; 0.41% positivity for CD200)
and UCBMSC 2 (Figure 1 H; 0.50% positivity for CD200).
hMSCs were positive for the cell surface antigens CD90, CD73,
CD105, CD49e, CD44 and HLA-ABC, and negative for CD34,
CD19, CD45, HLA-DR and CD14 (data not shown). All eight
hMSC lines therefore conformed with the surface marker
definition assembled by the International Society for Cellular
Therapies [41]. The CD200 expression was also confirmed by
immunofluorescent staining in which CD200Hi 1 (Figure 1 I),
CD200Lo 1 (Figure 1 J) and UCBMSC 1 (Figure 1 K) were
selected to demonstrate the differences in CD200 expression on
cell surface. For CD200Hi 1, most of the cells were positive for
CD200 Positive hMSC Suppress Macrophage-Like Cells
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were positive for CD200 and UCBMSC 1 were completely
negative. Regardless, CD200Lo 1 and UCBMSC 1 were CD90
positive. The further passage of the cells in vitro did not change
dramatically the CD200 expression on the cell surface of hMSCs
as can be seen with the CD200Hi 2 BMMSC line (Table 2).
IL-10 and TNF-a Secretion from Macrophage-like Cells Is
Modulated by CD200Hi 1 BMMSC Line
THP-1 cells were differentiated into the macrophage-like cells
by incubating for 48 hours in PMA (100 ng/ml) containing
medium. The differentiation was seen as an attachment of the cells
to the bottom of culture plates and an induced secretion of TNF-a
and IL-10 (Figure 2.). The addition of LPS increased TNF-a
secretion (mean6SD of three independent replicates) after 24 h
culture whereas IFN-c caused only mild increase or had no effect
on the TNF-a secretion when compared to un-stimulated THP-1
macrophage-like cells alone. The TNF-a concentration increased
from 1763.56207.2 pg/ml to 5002.36455 pg/ml after addition
of LPS and from 1763.56207.2 to 2510.3692.2 pg/ml after
addition of IFN-c respectively (Figure 2A). The co-culture with
hMSCs inhibited TNF-a secretion from IFN-c activated THP-1
macrophage-like cells from 2510.3692.2 pg/ml to 1337.06
53.7 pg/ml (p,0.001) whereas hMSCs had no significant impact
on TNF-a secretion of LPS activated THP-1 macrophage-like cells
where TNF-a concentration was 5002.36455 pg/ml in activated
THP-1 cells alone and 5790.56116.7 pg/ml in co-culture with
hMSCs. LPS or IFN-c did not induce significant IL-10 secretion
from THP-1 macrophage-like cells (Figure 2B). However, the
addition of hMSCs induced IL-10 secretion of THP-1 macro-
phage-like cells in the presence of both activators. IL-10
concentration changed from 86.9618.6 pg/ml to 444.346
29.9 pg/ml in the presence of LPS (p,0.001) and from
47.063.8 pg/ml to 140.6614.0 pg/ml (p,0.01) in the presence
of IFN-c (Figure 2B). The hMSC lines showed negligent IL-10 or
TNF-a secretion under all tested condition. When THP-1
differentiated macrophage-like cells were grown alone their
morphology resembled macrophages (Figure 2C). In co-cultures,
hMSCs were always attached into the bottom of culture plates and
most of the THP-1 macrophage-like cells seem to form aggregates
on the top of the hMSCs (Figure 2DE).
IFN-c Activated THP-1 Macrophage-like Cells Are
Sensitive to hMSC Mediated Inhibition of TNF-a Secretion
The ability of hMSCs to inhibit TNF-a secretion differed
between LPS and IFN-c stimulated THP-1 macrophage-like cells.
The eight hMSC lines were co-cultured for 24 hours with THP-1
macrophage-like cells in the presence of LPS or IFN-c and TNF-a
secretion from THP-1 macrophage-like cells in co-cultures were
compared to TNF-a secretion of IFN-c or LPS activated THP-1
macrophage-like cells alone (Figure 3). The presence of hMSCs
decreased TNF-a secretion from IFN-c activated THP-1 macro-
phage-like cells from 100% to 64.9%619.5% whereas when
hMSCs were co-cultured with LPS activated THP-1 macrophage-
like cells there were practically no differences in TNF-a secretion
when compared to LPS activated THP-1 macrophage-like cells
Table 1. Flow cytometry analysis of CD200 expression in hMSCs.
hMSC Lines
hMSC Lines Selected
in Experiments
Positivity for
CD200 (%)
Classification based
on CD200 Source Age (year) and Gender
hMSC 1 CD200Hi 1 52.53 CD200Hi Bone Marrow 58, female
hMSC 2 CD200Hi 2 69.59 CD200Hi Bone Marrow 16, female
hMSC 3 CD200Me 1 26.86 CD200Me Bone Marrow 35, female
hMSC 4 CD200Me 2 17.21 CD200Me Bone Marrow 16, male
hMSC 5 CD200Lo 1 7.50 CD200Lo Bone Marrow 10, male
hMSC 6 CD200Lo 2 8.31 CD200Lo Bone Marrow 70, male
hMSC 7 UCBMSC 1 0,50 UCBMSC Umbilical Cord Blood 0, male
hMSC 8 UCBMSC 2 0.41 UCBMSC Umbilical Cord Blood 0, male
hMSC 9 - 0.40 UCBMSC Umbilical Cord Blood 0, female
hMSC 10 - 11.41 CD200Me Bone Marrow 63, female
hMSC 11 - 26.45 CD200Me Bone Marrow 20, male
hMSC 12 - 27.18 CD200Me Bone Marrow 69, male
hMSC 13 - 11.64 CD200Me Bone Marrow 54, male
hMSC 14 - 5.95 CD200Lo Bone Marrow 55, male
hMSC 15 - 13.58 CD200Me Bone Marrow 17, female
hMSC 16 - 16.17 CD200Me Bone Marrow 40, male
hMSC 17 - 8.62 CD200Lo Bone Marrow 62, female
hMSC 18 - 28.17 CD200Me Bone Marrow 58, male
hMSC 19 - 11.95 CD200Me Bone Marrow 17, female
hMSC 20 - 14.67 CD200Me Bone Marrow 38, male
Positivity for CD200 was determined by flow cytometry and a negative control was used individually by each line in gating since the different autofluorescence of hMSC
lines.
Abbreviations: hMSCs, human mesenchymal stem cell; CD200Hi, bone marrow derived mesenchymal stem cell line with 50–70% positivity for CD200; CD200Me, bone
marrow derived mesenchymal stem cell line with 10–29% positivity for CD200; CD200Lo, bone marrow derived mesenchymal stem cell line with 2–9% positivity for
CD200; UCBMSC, umbilical cord blood derived mesenchymal stem cells CD200 negative.
doi:10.1371/journal.pone.0031671.t001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31671Figure 1. CD200 expression in hMSCs. Flow cytometry analysis showed that hMSC lines had different proportion of cells positive for CD200. A)
CD200Hi 1 BMMSC, B) CD200Hi 2 BMMSC, C) CD200Me 1 BMMSC, D) CD200Me 2 BMMSC, E) CD200Lo 1 BMMSC, F) CD200Lo 2 BMMSC, G) UCBMSC 1
and H) UCBMSC 2. The CD200 positivity was determined by a negative control individually since the different autofluorescent of hMSC lines. An
immunofluorescent staining of cell surface antigens showed that hMSCs labeled with PE-conjugated anti-human CD200 (red) and FITC-conjugated
anti-human CD90 (green) express CD200 differentially whereas they were all positive for CD90, I) CD200Hi 1 BMMSC (magnification 4006), J)
CD200Lo 1 BMMSC (magnification 4006) and K) UCBMSC 1 (magnification 4006). CD200-PE and CD90-FITC were stained against nuclear marker
Hoechst (Blue).
doi:10.1371/journal.pone.0031671.g001
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was greater in IFN-c primed THP-1 macrophage-like cells when
compared to LPS activated ones (p,0.01).
CD200 Expression is Linked to the Capability of BMMSCs
to Inhibit TNF-a Secretion from IFN-c Activated
Macrophage-like Cells
The immunofluorescent staining of THP-1 macrophage-
like cells with anti-human CD200R did not show CD200R
expression (Figure 4 A,D). In addition, the LPS activated THP-
1 macrophage like cells did not reveal clear CD200R expression
(Figure 4 B,E). However, the IFN-c activated THP-1
macrophage-like cells showed clear expression of CD200R on
cell surface (Figure 4 C,F). Eight hMSC lines were selected to
the co-cultures with IFN-c or LPS activated THP-1 macrophage-
Figure 2. An exemplary co-culture experiment shows that hMSCs can modulate cytokine secretion of THP-1 macrophage-like cells.
A) CD200Hi 1 were co-cultured with THP-1 macrophage-like cells in presence and absence of LPS (100 ng/ml) or INF-c (100 ng/ml) and TNF-a
secretion was measured. The co-culture of CD200Hi 1 with THP-1 macrophage-like cells decreased the TNF-a secretion when INF-c was present
whereas there were no significant differences in TNF-a secretion in the presence of LPS when compared to THP-1 macrophage-like cells alone. B) The
co-culture of CD200Hi 1 with THP-1 macrophage-like cells significantly increased IL-10 secretion in all conditions when compared to THP-1
macrophage-like cells alone. hMSC lines did not secreted significant levels of IL-10 or TNF-a in any conditions. Results are represented as a mean6SD
of three independent replicates. C) Light microscope analysis of THP-1 macrophage-like cells after 24 hours culture revealed that when THP-1
macrophage-like cells were cultured alone they were attached to the bottom of the wells and showed macrophage-like morphology (magnification
2006) where as in co-culture with hMSCs in presence of D) LPS or E) IFN-c they seemed to form aggregates on the top of hMSCs monolayer
(magnification 2006). Before co-culture, THP-1 macrophage-like cells were differentiated for 48 hours in PMA (100 ng/ml) supplemented medium as
described in materials and methods. ** and *** indicates two-sample t-test p-values p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0031671.g002
Table 2. Flow cytometry analysis of CD200 expression in
different passages.
CD200Hi 2 BMMSC line Positivity for CD200 (%)
Passage 1 57.7
Passage 2 69.6
Passage 4 67.8
Passage 6 68.0
Positivity for CD200 was determined by flow cytometry and a negative control
was used in gating.
Abbreviations: CD200Hi 2 BMMSC Line, bone marrow derived mesenchymal
stem cell line with 50–70% positivity for CD200.
doi:10.1371/journal.pone.0031671.t002
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cultures and THP-1 macrophage-like cells alone in presence of
LPS or IFN-c. In the presence of IFN-c, CD200Hi 1 decreased
TNF-a secretion from 100%612% to 43.561.7% (p,0.01),
CD200Hi 2 decreased TNF-a secretion form 100%612% to
40.3.364.8% (p,0.01), CD200Me 1 decreased TNF-a secretion
from 100%612% to 49.3.561.2% (p,0.01), CD200M2 de-
creased from 100%612% to 53.0%67.8% (p,0.01), C200Lo 1
decreased TNF-a secretion from 100%612% to 62.0%64.4%
(p,0.05), CD200Lo 2 decreased from 100%612% to
71.9%63.0% (p,0.05) whereas UCBMSC 1 and 2 had only
minor impact on TNF-a secretion (Figure 4G). The ability to
decrease TNF-a secretion from IFN-c activated THP-1 macro-
phage-like cells differed significantly between CD200Hi,
CD200Me and CD200Lo BMMSC lines (ANOVA p,0.001).
On the contrary, in the presence of LPS there was no correlation
between CD200 expression and the inhibition of TNF-a secretion
from THP-1 macrophage-like cells (Figure 4H). Only few
hMSC lines were able to significantly decrease TNF-a secretion
from LPS activated THP-1 macrophage-like cells after 24 hour
co-culture, CD200Me 1 decreased TNF-a secretion from
100%69.0% to 79.065.0% (p,0.05), CD200Lo 2 decreased
TNF-a secretion from 100%678.0% (p,0.05) and UCBMSC 2
decreased TNF-a secretion from 100%69.0 to 78.0%67.0%
(p,0.05; Figure 4H).
The Interference of CD200-CD200R Axis Decreased the
Capability of BMMSCs to Inhibit TNF-a Secretion from
IFN-c Activated THP-1 Macrophage-like Cells
Cells from CD200Hi 1, CD200Hi 2 and CD200Me 1 lines were
pre-treated with anti-human CD200 antibody and compared to
untreated cells in co-culture with IFN-c activated THP-1
macrophage-like cells. The untreated CD200Hi/Me control cells
decreased TNF-a secretion from IFN-c activated THP-1 cells
from 100% to 45.365.0%. In the CD200Hi/Me BMMSCs,
which had been pre-treated with anti-human CD200 antibody
(CD200ab block), TNF-a secretion decreased from 100% to only
68.765.0% (Figure 5A). Thus pre-treatment with anti-human
CD200 antibody decreased the capability of BMMSCs to inhibit
TNF-a secretion when compared to untreated control cells
(p,0.01). On the contrary, pre-treatment of cells from UCBMSC
1 line with anti-human CD200 antibody did not have a significant
impact in the ability to decrease TNF-a secretion from IFN-c
activated THP-1 macrophage-like cells when compared to
untreated ones (Figure 5B). The TNF-a secretion (mean6SD
of three independent replicates) changed from 100% to 10265.7%
in co-culture with untreated control cells and from 100% to
89.764.0% in co-culture with UCBMSCs which had been pre-
treated with anti-human CD200 antibody (Figure 5B). In
addition, there were no significant differences in the ability to
decrease TNF-a secretion from LPS activated THP-1 cells
between untreated CD200Hi/Me and CD200Hi/Me which had
been pre-treated with anti-human CD200 antibody. TNF-a
secretion changed from 100% to 103626.5% in co-culture with
un-treated controls and from 100% to 91.0612.0% in co-culture
with anti-human CD200 antibody pre-treated CD200Hi/Me
BMMSCs respectively (Figure 5C). These results also indicate
that IFN-c primed THP-1 cells responded to BMMSCs in a
CD200-CD200R dependent manner.
Discussion
The immunomodulative properties of hMSCs from different
sources have been widely studied in several immune cell models
[11–13,15,21,22]. However, the interaction between hMSCs and
human macrophages has received little attention even though
macrophages are key players in innate immunity [37,38]. Studies
on murine cells are also in line with findings in human cells [42].
The present study has, to our knowledge, been the first to ever to
demonstrate the variable CD200 expression from 20 different
hMSC lines. Moreover, we have also been able to elucidate the
role of CD200-CD200R axis in hMSCs mediated immunosup-
pression of THP-1 macrophage-like cells. THP-1 monocytes can
be differentiated into macrophage-like cells by various agents, such
as PMA and vitamin D, and these cells have shown to possess
properties similar to tissue resident macrophages [43–46]. In
addition, others have previously shown that THP-1 macrophage-
like cells can be used to study the interactions between
macrophages and hMSCs [37].
The expression of CD200 in hMSCs has been previously
published [27], however we have been able to show also
differences in the number of CD200 positive cells in samples
cultured from different donors. In addition, our study revealed that
none of the three UCBMSC lines expressed CD200. However, all
lines used in this work showed characteristics cell surface antigens
for hMSCs. Moreover, the extensive passaging of the CD200
positive hMSCs did not have any effect on CD200 expression with
reference to the characteristics of hMSCs. No systematic
correlation between immunosuppression efficiency and age of
BMMSC donors was evident, which could, at least partly, be due
Figure 3. hMSCs inhibit TNF-a secretion from macrophage-like
cells more efficiently in the presence of IFN-c. When hMSCs were
co-cultured with THP-1 macrophage-like cells for 24 hours in the
presence of IFN-c the decrease in TNF-a secretion was significantly
greater when compared to co-culture in the presence of LPS. Results are
represented as a mean6SD of co-cultures of eight different hMSC lines.
The TNF-a concentration from supernatants of LPS and IFN-c stimulated
THP-1 macrophage-like cells alone were indicated as 100% and TNF-a
concentration of supernatants from co-cultures with different hMSC
lines were compared to that. Before experiment, THP-1 macrophage-
like cells were differentiated 48 hours in PMA (100 ng/ml) supplement-
ed medium as described in materials and methods. ** indicates two-
sample t-test p-value p,0.01.
doi:10.1371/journal.pone.0031671.g003
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shown to correlate with the ability of BMMSCs to inhibit TNF-a
secretion of THP-1 macrophage-like cells in presence of IFN-c
even at rather low amount of samples which could underline the
physiological significance of such signaling. The CD200 could be a
potential marker of a more immunosuppressive hMSC population.
Figure 4. Immunnohistochemical analysis of CD200R expression in macrophages, the role of CD200-CD200R axis in hMSCs
mediated immunosuppression. The immunofluorescent staining with PE-conjugated anti-human CD200R (red) against nuclear marker Hoechst
(blue) revealed interesting differences in CD200R expression between A,D) un-stimulated (24 h culture without LPS or IFN-c) THP-1 macrophage-like
cells (magnification 4006) B,E) LPS stimulated (100 ng/ml for 24 h) THP-1 macrophage-like cells (magnification 4006) and C,F) IFN-c stimulated
(100 ng/ml for 24 h) THP-1 macrophage-like cells (magnification 4006). CD200R expression was clearly evident only after IFN-c stimulation whereas
LPS stimulated and unstimulated THP-1 macrophage-like cells did not revealed clear CD200R expression. G) CD200Hi, CD200Me and C200Lo BMMSC
lines decreased significantly TNF-a secretion from THP-1 macrophage-like cells in presence of IFN-c whereas UCBMSC lines did not. There were also
significant differences between CD200Hi, CD200Me and CD200Lo BMMSC lines in their ability to inhibit TNF-a secretion of IFN-c (100 ng/ml for 24 h)
activated THP-1 macrophage-like cells whereas H) there were no correlation between CD200 expression and the ability of hMSCs to decrease TNF-a
secretion from THP-1 macrophage-like cells in presence of LPS (100 ng/ml for 24 h). Only CD200Me 1, CD200Lo 2 and UCBMSC 2 lines had significant
reduction in TNF-a secretion. Results are represented as a mean6SD of three independent replicates. TNF-a concentration in supernatants from LPS
or IFN-c activated THP-1 macrophage-like cells alone were indicated as 100% and TNF-a concentration in supernatants from co-cultures with different
hMSC lines were compared to that. Before co-cultures, THP-1 macrophage-like cells were differentiated 48 hours in PMA (100 ng/ml) supplemented
medium as described in materials and methods. * and ** indicates two-sample t-test p-values p,0.05 and p,0.01. !!! indicates one way analysis of
variance (ANOVA) between CD200Hi, CD200Me and CD200Lo BMMSCs p-value p,0.001.
doi:10.1371/journal.pone.0031671.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31671Figure 5. Pre-treatment of hMSCs with CD200 antibody was performed to study the role of CD200-CD200r axis in hMSC mediated
immunosuppression. A) The ability of CD200Hi/Me BMMSCs to inhibit TNF-a secretion of IFN-c activated THP-1 macrophage-like cells can be
prevented by pre-treatment with anti-human CD200 antibody whereas the pre-treatment with anti-human CD200 antibody had no effect on B)
UCBMSC in presence of IFN-c and C) CD200Hi/Me BMMSCs when co-cultured with LPS activated THP-1 macrophage-like cells. THP-1 macrophage-like
cells were activated in co-cultures with 100 ng/ml LPS or 100 ng/ml IFN-c for 24 hours and after that supernatants were collected. Results are
represented as a mean6SD of co-cultures with three different CD200Hi/Me hMSC lines and mean6SD of three independent replicates with one
UCBMSC line. The blocking of hMSCs with anti-human CD200 antibody was performed by pre-incubating part of the hMSCs with CD200 antibody for
20 min at room temperature and then washed twice with PBS whereas other part of the cells remained untreated. TNF-a concentration in
supernatants from LPS or IFN-c activated THP-1 macrophage-like cells alone were indicated as 100% and TNF-a concentration in supernatants from
co-cultures with different hMSC lines, anti-human CD200 pre-treated and control ones, were compared to that. Before co-cultures, THP-1
macrophage-like cells were differentiated 48 hours in PMA (100 ng/ml) supplemented medium as described in materials and methods. ** indicates
two-sample t-test p-value p,0.01.
doi:10.1371/journal.pone.0031671.g005
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UCBMSCs and BMMSCs and also between BMMSC lines
remains to be elucidated. One explanation for the lack of CD200
in UCBMSC may be the differences in the micro environment in
vivo, since BMMSCs reside in close proximity with macrophage
progenitors unlike UCBMSCs [47,48]. This may also explain the
relatively low capability of UCBMSCs to inhibit TNF-a secretion
from THP-1 macrophage-like cells when compared to BMMSCs.
Moreover, CD200-CD200R axis also participates in the regula-
tion of bone mass, which may be one plausible explanation for the
differences in CD200 expression between UCBMSCs and
BMMSCs [49].
Interestingly, the ability of hMSCs to suppress TNF-a secretion
of IFN-c stimulated THP-1 macrophage-like cells was significantly
greater when compared to LPS activated ones. IFN-c did not
reveal clear induction of TNF-a secretion from THP-1 macro-
phage-like cells unlike that of LPS. This observation is in line with
a recent study where proteome bioprofiling of differently activated
macrophages were studied [10]. The same study also showed that
IFN-c and LPS caused different protein profiles which were
distinguished from basal macrophages [10]. These results clearly
demonstrate the differences in the activity of macrophages
between IFN-c and LPS stimulation, in which the IFN-c seems
to prime macrophages whereas LPS causes more drastic
activation. Even thought IFN-c did not cause a clear increase in
TNF-a secretion from THP-1 macrophages, the key role of IFN-c
in many inflammatory conditions is well known. For instance,
IFN-c together with LPS is prerequisite for the development of
inflammatory bowel disease [8] and the role of IFN-c has also
been demonstrated in development of atherosclerosis [6,9] and in
Crohn’s disease [7], which are only a few of the inflammatory
conditions in which macrophages are also implicated.
In previous studies, LPS has been used as an activator for
macrophages and it has been shown that hMSCs inhibit TNF-a
secretion [37,38]. Evidently, our results are not in line with such
data, possibly due to the differences in co-culture protocols.
Previous studies have measured TNF-a production after 4 h LPS
stimulation whereas we used a 24 h time point. More specifically,
these observations may suggest that the ability of hMSCs to inhibit
LPS stimulated macrophages may be limited only to the early
phase whereas in presence of IFN-c hMSCs have more prolonged
effect on TNF-a secretion from macrophage-like cells. It is also
noteworthy, that many pro-inflammatory factors, such as TNF-a,
IFN-c and LPS modulate the immunosuppressive properties of
hMSCs [20,21,50]. Accordingly, it is also possible that LPS and
IFN-c may differently modulate the immunosuppression potential
of hMSCs, which may explain the differences. IFN-c has, for
example, been shown to regulate mesenchymal stem cells via
activation of indoleamine 2,3 dioxygenase, which suggests that a
complex network of inflammation control could exists in vivo
[21,51]. However, such a hypothesis is extremely challenging to
prove in our study, as during co-culture hMSCs are exposed to
several different cytokines which most likely have combinatorial
effects. Regardless, our observations suggest that also other
activators than LPS alone, should be considered, when the
immunosuppressive potential of hMSC-based cellular products is
determined. Supporting such a conclusion, the previous study has
also shown that using combination of IFN-c and LPS leads to a
more differential activation of macrophages and the presence of
both stimulators are needed to develop bowel inflammatory
disease [8].
THP-1 macrophage-like cells expressed CD200R only after
PMA treatment following IFN-c activation. This observation is in
accord with the findings which showed that CD200Hi BMMSC
lines decreased the TNF-a secretion from THP-1 macrophage-like
cells in presence of IFN-c more efficiently when compared to
CD200Lo BMMSC lines. However, there were no differences
when these cell lines were co-cultured in the presence of LPS. Also
these findings are well in line with previous data which has
demonstrated that the CD200R agonist had immunosuppressive
effect only when mouse peritoneal macrophages were activated
with IFN-c, whereas LPS-stimulated ones were unaffected [52].
However, although CD200 negative UCBMSCs showed the
weakest inhibition capacity of TNF-a secretion, the present study
can not conclude that the lack of CD200 can explain the
differences as the UCBMSCs represent a different hMSC type.
Conflicting results have also been published on the role of the
CD200-CD200R axis in THP-1 cells [53,54]. The lack of
CD200R expression in the study by Salata et al. [54] may
possibly be due to different THP-1 differentiation and activation
protocols, as we have used longer PMA treatments with higher
concentration in accordance with Langlais et al [53]. In addition, a
recent study has shown that the maturity of THP-1 macrophages
is related to the duration of PMA treatment and the duration of
the incubation time without PMA [55].
The present study has shown that the interference of CD200
binding to CD200R weakened significantly the ability of
BMMSCs to inhibit TNF-a secretion from IFN-c activated
THP-1 macrophage-like cells. On the other hand, the interference
of CD200-CD200R interaction did not fully prevent the capability
of hMSCs to suppress TNF-a secretion of IFN-c activated THP-1
macrophage-like cells but decreased this capability to the same
level as was evident in CD200Lo BMMSC lines. This suggests that
BMMSCs may also have other mechanisms for altering TNF-a
secretion of THP-1 macrophage-like cells in addition to the
CD200-CD200r axis. The anti-human CD200 antibody used in
the present study was not specifically produced for blocking
experiments, but our results showed that the anti-human CD200
antibody pre-treatment had no effect on the capability of
CD200Hi/Me BMMSC to inhibit TNF-a secretion in presence
of LPS (CD200R negative THP-1 macrophage-like cells) or
UCBMSCs to inhibit TNF-a secretion in presence of IFN-c
(CD200 negative), which support the reliability of our results.
The CD200-CD200r axis represents one specific interaction
between hMSCs and immune cells in the wide and complex set of
different immunosuppressive mechanisms which interact parallel.
The exact role of the CD200 in that process remains to be
elucidated and needs to be clarified in vivo inflammatory disease
models in future. It is also possible, that CD200 may just be a sign
of a cell population with distinct immunosuppressive capacity. It is
to be noted, that this capacity can not be detected by the
conventional hMSC characterization panel. By using different
immune cell models, future studies should also focus on testing the
immunosuppressive potential of CD200Hi, CD200Me, CD200Lo
and UCBMSC, as previous studies have suggested that CD200-
CD200R axis may not be as relevant in modulation of adaptive
immunity [56,57]. In the present study, all hMSC lines did induce
significant IL-10 secretion from THP-1 macrophage-like cells,
which was in line with previous studies [37,38], but it was not in
line with CD200 expression (data not shown). Hence, as the
immunological mechanisms are very complex there is still much
room for other, CD200 independent immunosuppressive mech-
anism for hMSCs. Moreover, further characterization of CD200
positive BMMSCs in future is critical because CD200 has also
been linked to cancer stem cells and tumors [58,59].
To conclude, this study has clearly clarified for the first time the
role of CD200 in BMMSCs mediated inhibition of TNF-a
secretion from macrophages in the presence of IFN-c. CD200Hi
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31671BMMSCs showed higher inhibition of TNF-a secretion from
THP-1 macrophage-like cells when compared to CD200Lo
BMMSC. The results indicate that CD200 could be a potential
candidate for predicting the immunosuppressive activity of
cultured BMMSCs in clinical conditions, where activated
macrophages play a key role.
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